Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Developments in oligometastatic hormone-sensitive prostate cancer.

Tran PT, Ost P.

World J Urol. 2019 Dec;37(12):2545-2547. doi: 10.1007/s00345-019-03009-w. No abstract available.

PMID:
31705198
2.

Developments in oligometastatic hormone-sensitive prostate cancer.

Chow K, McCoy P, Stuchbery R, Corcoran NM, Hovens CM.

World J Urol. 2019 Dec;37(12):2549-2555. doi: 10.1007/s00345-018-2542-x. Epub 2018 Oct 31.

PMID:
30382379
3.

Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer.

Patel PH, Chaw CL, Tree AC, Sharabiani M, van As NJ.

World J Urol. 2019 Dec;37(12):2615-2621. doi: 10.1007/s00345-019-02873-w. Epub 2019 Jul 25.

4.

Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology.

Joice GA, Rowe SP, Pienta KJ, Gorin MA.

Curr Opin Urol. 2017 Nov;27(6):533-541. doi: 10.1097/MOU.0000000000000449. Review.

PMID:
28863016
5.

Evolving Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer.

Clement JM, Sweeney CJ.

J Oncol Pract. 2017 Jan;13(1):9-18. doi: 10.1200/JOP.2016.018523. Epub 2017 Jan 3. Review.

PMID:
28045610
6.

The role of hormone therapy and chemotherapy in oligometastatic prostate cancer.

Miura Y, Horie S.

ESMO Open. 2019 Mar 12;4(Suppl 1):e000471. doi: 10.1136/esmoopen-2018-000471. eCollection 2019. Review.

7.

A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).

Radwan N, Phillips R, Ross A, Rowe SP, Gorin MA, Antonarakis ES, Deville C, Greco S, Denmeade S, Paller C, Song DY, Diehn M, Wang H, Carducci M, Pienta KJ, Pomper MG, DeWeese TL, Dicker A, Eisenberger M, Tran PT.

BMC Cancer. 2017 Jun 29;17(1):453. doi: 10.1186/s12885-017-3455-6.

8.

Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer.

Kothari G, Ost P, Cheung P, Blanchard P, Tree AC, van As NJ, Lo SS, Moghanaki D, Loblaw A, Siva S.

Curr Oncol Rep. 2019 Mar 27;21(5):43. doi: 10.1007/s11912-019-0791-5. Review.

PMID:
30919165
9.

Risk stratification in oligometastatic prostate cancer: where are we and what do we need?

Morgans AK, Hussain M.

Curr Opin Urol. 2017 Nov;27(6):547-552. doi: 10.1097/MOU.0000000000000439. Review.

PMID:
28825922
10.

A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer.

Ross AE, Hurley PJ, Tran PT, Rowe SP, Benzon B, Neal TO, Chapman C, Harb R, Milman Y, Trock BJ, Drake CG, Antonarakis ES.

Prostate Cancer Prostatic Dis. 2019 Oct 14. doi: 10.1038/s41391-019-0176-8. [Epub ahead of print]

PMID:
31611635
11.

A Multicenter Prospective Clinical Trial of 68Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging.

McCarthy M, Francis R, Tang C, Watts J, Campbell A.

Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):801-808. doi: 10.1016/j.ijrobp.2019.03.014. Epub 2019 Mar 16.

PMID:
30890448
12.

Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO).

D'Angelillo RM, Francolini G, Ingrosso G, Ravo V, Triggiani L, Magli A, Mazzeo E, Arcangeli S, Alongi F, Jereczek-Fossa BA, Pergolizzi S, Pappagallo GL, Magrini SM.

Crit Rev Oncol Hematol. 2019 Jun;138:24-28. doi: 10.1016/j.critrevonc.2019.03.014. Epub 2019 Apr 1. Review.

PMID:
31092381
13.

OLIGOPELVIS - GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer.

Supiot S, Rio E, Pacteau V, Mauboussin MH, Campion L, Pein F.

BMC Cancer. 2015 Sep 25;15:646. doi: 10.1186/s12885-015-1579-0.

14.

Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.

Battaglia A, De Meerleer G, Tosco L, Moris L, Van den Broeck T, Devos G, Everaerts W, Joniau S.

Eur Urol Oncol. 2019 Mar;2(2):174-188. doi: 10.1016/j.euo.2018.09.005. Epub 2018 Oct 9. Review.

PMID:
31017094
15.

Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT.

Bouman-Wammes EW, van Dodewaard-De Jong JM, Dahele M, Cysouw MCF, Hoekstra OS, van Moorselaar RJA, Piet MAH, Verberne HJ, Bins AD, Verheul HMW, Slotman BJ, Oprea-Lager DE, Van den Eertwegh AJM.

Clin Genitourin Cancer. 2017 Oct;15(5):e773-e782. doi: 10.1016/j.clgc.2017.03.009. Epub 2017 Mar 29.

PMID:
28462855
16.

Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease.

Parikh NR, Huiza C, Patel JS, Tsai S, Kalpage N, Thein M, Pitcher S, Lee SP, Inouye WS, Jordan ML, Sanati H, Jafari L, Bennett CJ, Gin GE, Kishan AU, Reiter RE, Lewis M, Sadeghi A, Aronson WJ, Garraway IP, Rettig MB, Nickols NG.

BMC Cancer. 2019 Apr 1;19(1):291. doi: 10.1186/s12885-019-5496-5.

17.

Oligometastatic Prostate Cancer.

Navrátil J, Poprach A, Lakomý R, Kocák I, Vašina J, Krupa P, Vyzula R.

Klin Onkol. 2019 Spring;32(2):97-100. doi: 10.14735/amko201997. Review.

PMID:
30995848
18.

The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer.

Kim J, Park JS, Ham WS.

Investig Clin Urol. 2017 Sep;58(5):307-316. doi: 10.4111/icu.2017.58.5.307. Epub 2017 Aug 8. Review.

19.

Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting.

Aluwini SS, Mehra N, Lolkema MP, Oprea-Lager DE, Yakar D, Stoevelaar H, van der Poel H; Dutch Oligometastatic Prostate Cancer Working Group, Busstra M, de Jong IJ, de Reijke T, de Vries K, Heijmink S, Jenster G, Klaver S, Kneppers J, Lavalaye J, Leyten G, Moonen L, Nagaraj J, Noordzij W, Osanto S, Oving I, Schaake E, Scheenen T, Schoots I, Sedelaar M, Somford D, van den Berkmortel F, van der Hulle T, van der Voort van Zyp J, van Leeuwen P, van Moorselaar J, van Oort I, Vogel W, Westgeest H.

Eur Urol Oncol. 2019 Aug 7. pii: S2588-9311(19)30113-0. doi: 10.1016/j.euo.2019.07.010. [Epub ahead of print]

PMID:
31401014
20.

[Surgical treatment of local disease in metastatic prostate cancer.]

Gaya JM, Huguet J, Breda A, Palou J.

Arch Esp Urol. 2018 Mar;71(3):288-297. Review. Spanish.

PMID:
29633950

Supplemental Content

Support Center